1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B9ABE2FA695467760025867A002C48A4
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/B9ABE2FA695467760025867A002C48A4?OpenDocument
18
19OpenDocument
2035.170.64.36
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Product Launch Excellence

Document Excerpt: Pure Play Digital Launch: Launching a New Blockbuster Migraine Drug During a Global Pandemic

DB Image

Excerpt in Cart

ID: MD-765


Features:

33 Info Graphics

17 Data Graphics

78 Metrics

19 Narratives


Pages/Slides: 4


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5665 “Pure Play Digital Launch: Launching a New Blockbuster Migraine Drug During a Global Pandemic”.

Disclaimer: Biohaven is not affiliated with Best Practices, LLC and Biohaven has not sponsored, endorsed or supported this analysis.

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Biotech; Consumer Products


Companies Profiled:
Biohaven Pharmaceuticals; AbbVie; Amgen; Eli Lilly; Novartis

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.